Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 [R 788, fostamatinib] in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TASKI-3
- Sponsors Rigel Pharmaceuticals
- 24 Mar 2012 This trial is recruiting in France.
- 01 Feb 2011 Results published in the Arthritis and Rheumatism.
- 21 Oct 2009 Results were reported at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.